Treatment of myelodysplastic syndromes with low-dose oral 6-thioguanine
| Autor: | Thomas R. Spitzer, Hillard M. Lazarus, Edward D. Crum, Russell Weisman |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Administration Oral Gastroenterology Tioguanine Oral administration Internal medicine medicine Humans Thioguanine Aged Aged 80 and over Chemotherapy business.industry Myelodysplastic syndromes Middle Aged medicine.disease In vitro Peripheral Oncology Myelodysplastic Syndromes Pediatrics Perinatology and Child Health Toxicity Immunology Absolute neutrophil count Female business medicine.drug |
| Zdroj: | Medical and Pediatric Oncology. 16:17-20 |
| ISSN: | 1096-911X 0098-1532 |
| DOI: | 10.1002/mpo.2950160105 |
| Popis: | Several cytotoxic agents when used in vitro in very low concentrations have been shown to induce differentiation of leukemic cells. We treated 18 patients with myelodysplastic syndromes with low-dose oral 6-thioguanine (6-TG; 20 to 60 mg daily). Four patients demonstrated significant improvement in peripheral blood counts. An additional three patients had significant reductions in the percentage of leukemic myeloblasts in the marrow without a corresponding improvement in peripheral counts. With the exception of a fall in the peripheral neutrophil count in four patients requiring dose reductions, no toxicity was observed. Low-dose oral 6-TG gives a response rate in myelodysplastic syndromes similar to that of parenteral agents such as cytosine arabinoside. Given the ease of administration and lack of toxicity, oral 6-TG may be a useful treatment modality for these syndromes either alone or in combination with other differentiation-enhancing agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text